Hemodynamic effects of BTB-cyclic AMP in anesthetized dogs.
The hemodynamic effects of 8-benzylthio-N6-n butyl adenosine 3',5' cyclic monophosphate (BTB-cAMP) were studied in anesthetized dogs. BTB-cAMP was given intravenously in doses of 1, 3 and 9 mg/kg, respectively. BTB-cAMP induced dose-dependent increases in heart rate, max LV dp/dt, cardiac output and stroke volume, and decreases in mean blood pressure and total peripheral resistance. BTB-cAMP had less of an effect on heart rate and blood pressure than dibutyryl cAMP (DB-cAMP), but showed a greater effect in augmenting cardiac contractility, with earlier manifestations of maximum action. Although the duration of its action is shorter, BTB-cAMP has possible therapeutic applications in cardiovascular diseases such as cardiogenic shock and congestive heart failure. It may also be a better agent than DB-cAMP for the treatment of patients with congestive heart failure because of a less potent hypotensive effect.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003994:Bucladesine / Q000494:pharmacology; D000242:Cyclic AMP / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D004285:Dogs; D005260:Female; D006333:Heart Failure / Q000188:drug therapy; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D012770:Shock, Cardiogenic / Q000188:drug therapy; D013318:Stroke Volume / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
C040965:8-benzylthio-N(6)-n-butyladenosine cyclic-3,5'-monophosphate; D003994:Bucladesine; D000242:Cyclic AMP